How to Cite
Abstract
The structural pulmonary disease is defined as any pathology that alters the architecture of lower airway and lung parenchyma, which predisposes to microbial colonization. Among the diseases classified as structural pulmonary disease we find chronic obstructive pulmonary disease, bronchiectasis and caverns as sequelae of necrotizing diseases. Acute manifestation of lower respiratory symptoms constitutes an exacerbation that deteriorates clinical baseline condition, so it is essential to establish the role of infections as cause of these exacerbations; the most common infectious agents are: Haemophilus influenzae, Streptococcus pneumoniae and viral pathogens in chronic obstructive pulmonary disease and Haemophilus influenzae, Moraxella catarrhalis and Pseudomonas aeruginosa in bronchiectasis. In exacerbations of fibrocavitary sequelae are the same germs than other structural alterations, besides fingi and mycobacteria in about 40%. MÉD.UIS. 2015;28(1):117-123.
Keywords: Chronic Obstructive Pulmonary Disease. Bronchiectasis. Infection.
References
Lucena P. Significación clínica del aislamiento de Aspergillus spp. en secreciones respiratorias del paciente con enfermedad pulmonar estructural [Tesis]. Madrid: Universidad Complutense de Madrid; 2011.
Sethi S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355-65.
Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343-9.
Ourari-Dhahri B, Zaibi H, Ben Amar J, El Gharbi L, Baccar MA, Azzabl S, et al. Symptoms and natural history of hospital chronic obstructive pulmonary disease. Tunis Med. 2014;92(1):12-17.
McShane PJ, Naureckas ET, Tino G, Strek ME. Non- cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647-56.
Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014;383(9924):1230-9.
Kumar V, Abbas A, Fausto N, Aster J. Robbins y Cotran. Patología estructural y funcional. 8a ed. Barcelona: Elsevier; 2010.
Asociación Latinoamericana de Tórax (ALAT). Recomendaciones para el diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica (EPOC)[Internet]. 2011. Disponible en: https://www.alatorax.org/guia-epoc-%E2%80%93-alat/ recomendaciones-para-el-diagnostico-y-tratamiento-de-la- enfermedad-pulmonar-obstructiva-cronica-epoc-abril-2011
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370 (9589):765-73.
Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(5):693-718.
Calle M, Chacón BM, Rodríguez JL. Exacerbación de la EPOC. Arch Bronconeumol. 2010;46(Suppl 7):21-5.
Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, et al. Airway Bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(4):356-61.
Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF. Infammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care
Med. 2008;177(5):491-7.
Kherad O, Kaiser L, Bridevaux PO, Sarasin F, Thomas Y, Janssens JP, et al. Upper-respiratory viral infection, biomarkers and COPD exacerbations. Chest. 2010;138(4):896-904.
Fauci A, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison Principios de Medicina Interna. 17a ed. Barcelona: McGraw Hill; 2011.
Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013;187(10):1118-26.
O’Donnell A. E. Bronchiectasis. Chest. 2008;134(4):815-23.
Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, Solé T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57(1):15-9.
Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400-7.
Martinez MA. Monografías en neumología: Bronquiectasias no debidas a fibrosis quística [Monografia en Internet]. Zaragoza: Neumología y salud; 2008. Disponible en: http://www. neumologiaysalud.es/descargas/M1/M1.pdf
Cantón R, Fernández A, Gómez E, del Campo R, Meseguer MA. Infección bronquial crónica: el problema de Pseudomonas aeruginosa. Arch Bronconeumol. 2011; 47(Supl 6):8-13.
Ocampo ML, Salmón JA, Noguera VD, Zabala OC. Bronquiectasias: revisión bibliográfica. Rev posgrado VIa Cátedra Med. 2008;(182):16-9.
White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med.
;106(3):356-60.
Hormiga CM, Villa D. Situación de la tuberculosis en Santander 2005-2008. Rev OSPS. 2009;4(3):4-11.
Kim HY, Song KS, Goo JM, Lee JS, Lee KS, Lim TH. Thoracic sequelae and complications of tuberculosis. RadioGraphics. 2001;21(4):839-60.
Domínguez F, Fernández B, Pérez M, Marín B, Bermejo C. Clínica y radiología de la tuberculosis torácica. An Sist Sanit Navar. 2007;30(Suppl 2):33-48.
Rammaert B, Goyet S, Tarantola A, Hem S, Rith S, Cheng S, et al. Acute lower respiratory infections on lung sequelae in Cambodia, a neglected disease in highly tuberculosis-endemic
country. Respir Med. 2013;107(10):1625-32.
Amorim E, Saad R Jr, Stirbulov R. Spirometry evaluation in patient with tuberculosis sequelae treated by lobectomy. Rev Col Bras Cir. 2013;40(2):117-20.